omeprazole has been researched along with Cholera Infantum in 98 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our purpose was to determine whether omeprazole use during pregnancy is associated with an increased risk of malformations, spontaneous abortions, decreased birth weight, or perinatal complications." | 9.08 | The safety of omeprazole during pregnancy: a multicenter prospective controlled study. ( Addis, A; Bonati, M; Koren, G; Lalkin, A; Loebstein, R; Mastroiacovo, P; Mazzone, T; Ramezani-Namin, F; Vial, T, 1998) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 8.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| "Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells." | 7.74 | Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008) |
| "GI symptoms in children with cystinosis receiving cysteamine are often acid-mediated and improve with omeprazole." | 7.72 | The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. ( Deutsch, R; Dohil, R; Newbury, RO; Schneider, JA; Sellers, ZM, 2003) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| "Our purpose was to determine whether omeprazole use during pregnancy is associated with an increased risk of malformations, spontaneous abortions, decreased birth weight, or perinatal complications." | 5.08 | The safety of omeprazole during pregnancy: a multicenter prospective controlled study. ( Addis, A; Bonati, M; Koren, G; Lalkin, A; Loebstein, R; Mastroiacovo, P; Mazzone, T; Ramezani-Namin, F; Vial, T, 1998) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 4.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| " We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period." | 4.83 | Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. ( Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G, 2006) |
| " pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan." | 4.82 | Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. ( Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M, 2003) |
| "Perhaps older drugs to treat ulcers, such as antacids, are just as effective as the newer drugs, but veterinarians have all but abandoned these drugs in favor of H2-receptor antagonists, sucralfate, and omeprazole." | 4.78 | Antiulcer therapy. ( Papich, MG, 1993) |
| "Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells." | 3.74 | Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008) |
| "GI symptoms in children with cystinosis receiving cysteamine are often acid-mediated and improve with omeprazole." | 3.72 | The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. ( Deutsch, R; Dohil, R; Newbury, RO; Schneider, JA; Sellers, ZM, 2003) |
| "To carry out a economic evaluation of diclofenac/misoprostol in the treatment of rheumatoid arthritis and osteoartritis when comparing with diclofenac alone, diclofenac + omeprazol, and diclofenac + ranitidine." | 3.70 | [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases]. ( Soto Alvarez, J, 2000) |
| " Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)." | 2.78 | Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. ( Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013) |
| "Pantoprazole was superior to misoprostol (p < 0." | 2.71 | Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. ( Dietrich, K; Fischer, R; González-Carro, P; Lühmann, R; Straszak, A; Stupnicki, T; Terjung, A; Thomas, KB, 2003) |
| "Ketoprofen monotherapy has been shown to be generally equivalent to other NSAIDs when used in the treatment of OA." | 2.48 | Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. ( Gigante, A; Tagarro, I, 2012) |
| " As there are specific characteristics of these patients that could alter the pharmacokinetics of the drugs, studies need to be performed to determine the most suitable dose and dosage interval." | 2.46 | Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients. ( López-Herce, J; Solana, MJ, 2010) |
| "Esomeprazole has a good tolerability profile and a low potential for drug interaction." | 2.45 | The pharmacology of esomeprazole and its role in gastric acid related diseases. ( Saccar, CL, 2009) |
| " Protonic pump inhibitors (PPI) are considered to be the correct therapy in the treatment of peptic ulcers, as they have proven to be safe and efficient." | 2.44 | [Protonic pump inhibitors in kidney transplant patients: efficacy and safety]. ( Cianciolo, G; Comai, G; Feliciangeli, G; Stefoni, S, 2007) |
| "Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease." | 2.43 | Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. ( Robinson, M, 2005) |
| " Intravenous pantoprazole has been shown to maintain acid suppression in patients switched from oral PPIs, so no change in dosage is required when switching from one formulation to the other." | 2.41 | Switching between intravenous and oral pantoprazole. ( Pisegna, JR, 2001) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion." | 2.40 | Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. ( Langtry, HD; Wilde, MI, 1997) |
| "The selection of agents to treat patients with acid-related gastrointestinal diseases requires knowledge of their efficacy, tolerability, and ease of dosing among individuals with differing disease severities and other baseline characteristics." | 2.40 | Review article: rabeprazole's profile in patients with gastrointestinal diseases. ( Barth, J; Humphries, TJ, 1999) |
| "Omeprazole remains a treatment of choice in patients with Zollinger-Ellison syndrome." | 2.39 | Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. ( McTavish, D; Wilde, MI, 1994) |
| "Renal failure has no influence on the pharmacokinetics of lansoprazole, but severe hepatic failure causes a significant decrease in clearance and an increase in the AUC and t1/2 of lansoprazole." | 2.39 | Clinical pharmacokinetics of lansoprazole. ( Flouvat, B; Landes, BD; Petite, JP, 1995) |
| " Moderate hypergastrinaemia occurs in some patients, especially if an omeprazole dosage of 40 mg/day is needed." | 2.39 | Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. ( Creutzfeldt, W, 1994) |
| "Omeprazole is a powerful inhibitor of gastric acid secretion." | 2.38 | Omeprazole. Overview and opinion. ( Holt, S; Howden, CW, 1991) |
| " Reviewing the manner of administration and stated indications for use of both drugs, we find omeprazole is often administered outside dosing recommendations, and both drugs are frequently administered for aims that are unlikely to be achieved when considering their known biological effects in dogs." | 1.56 | Prospective observational study of the use of omeprazole and maropitant citrate in veterinary specialist care. ( Glanemann, B; McCormack, R; Olley, L; Swann, JW, 2020) |
| "Malnutrition and gastrointestinal disorders are very common in children with cerebral palsy." | 1.34 | Impact of malnutrition on gastrointestinal disorders and gross motor abilities in children with cerebral palsy. ( Campanozzi, A; Capano, G; Del Giudice, E; Miele, E; Militerni, R; Romano, A; Scuccimarra, G; Staiano, A; Strisciuglio, C, 2007) |
| "Treatment with omeprazole or melatonin prevented this damage as well as the changes in biochemical parameters, and melatonin appeared to be more efficient than omeprazole in protecting the mucosa." | 1.33 | Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. ( Arbak, S; Dülger, GA; Ersoy, Y; Goren, FO; Sener, G; Ulusoy, NB, 2005) |
| " On logistic regression analysis, none of the confounding factors (sex, age, indication, chronic use of PPI, eradication protocol) were found to contribute to the discrimination between a negative (successful eradication) and a positive (failed eradication) 13CUBT." | 1.33 | Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication. ( Niv, Y, 2005) |
| "Fundic gland polyps have been described either in association with genetic polyposis syndromes of the colon, or in a sporadic form." | 1.33 | Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. ( Bellone, S; Caruso, S; Declich, P; Ferrara, A; Tavani, E, 2005) |
| "The study involved a search of the Food and Drug Administration's database for adverse events and drug interactions with omeprazole, lansoprazole or pantoprazole as primary or secondary suspect drug." | 1.32 | A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. ( Koelz, HR; Labenz, J; Petersen, KU; Rösch, W, 2003) |
| "Esomeprazole was also effective in patients with symptomatic GORD." | 1.31 | Esomeprazole: a review of its use in the management of acid-related disorders in the US. ( Dunn, CJ; Mallarkey, G; Scott, LJ; Sharpe, M, 2002) |
| " The pharmacokinetic parameters of omeprazole were: systemic clearance, 0." | 1.29 | Pharmacokinetics of intravenous omeprazole in children. ( Andre, J; Baudouin, V; Bellaich, M; Faure, C; Jacqz-Aigrain, E; Navarro, J; Rohrlich, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (4.08) | 18.7374 |
| 1990's | 28 (28.57) | 18.2507 |
| 2000's | 53 (54.08) | 29.6817 |
| 2010's | 12 (12.24) | 24.3611 |
| 2020's | 1 (1.02) | 2.80 |
| Authors | Studies |
|---|---|
| McCormack, R | 1 |
| Olley, L | 1 |
| Glanemann, B | 1 |
| Swann, JW | 1 |
| Andrade, PHS | 1 |
| Lobo, IMF | 1 |
| da Silva, WB | 1 |
| García-Torres, I | 1 |
| De la Mora-De la Mora, I | 1 |
| Hernández-Alcántara, G | 1 |
| Molina-Ortiz, D | 1 |
| Caballero-Salazar, S | 1 |
| Olivos-García, A | 1 |
| Nava, G | 1 |
| López-Velázquez, G | 1 |
| Enríquez-Flores, S | 1 |
| Kashour, T | 1 |
| Al-Tannir, M | 1 |
| Bahamid, R | 1 |
| Asif, HM | 1 |
| Zaidi, SF | 1 |
| Sugiyama, T | 1 |
| Akhtar, N | 1 |
| Usmanghani, K | 1 |
| Sharma, T | 1 |
| Bliden, K | 1 |
| Chaudhary, R | 1 |
| Tantry, U | 1 |
| Gurbel, PA | 2 |
| Zhang, W | 1 |
| Han, Y | 1 |
| Fort, JG | 2 |
| Schofield, D | 1 |
| Tursi, JP | 1 |
| Baranov, AA | 1 |
| Shcherbakov, PL | 1 |
| Saccar, CL | 1 |
| Solana, MJ | 1 |
| López-Herce, J | 1 |
| Wagner, S | 1 |
| Varet-Legros, MG | 1 |
| Fabre, C | 1 |
| Montastruc, JL | 1 |
| Bagheri, H | 1 |
| Yakoob, J | 1 |
| Abid, S | 1 |
| Abbas, Z | 1 |
| Jafri, SN | 1 |
| Gigante, A | 1 |
| Tagarro, I | 1 |
| Blackler, R | 1 |
| Syer, S | 1 |
| Bolla, M | 1 |
| Ongini, E | 1 |
| Wallace, JL | 1 |
| Bliden, KP | 1 |
| Jeong, YH | 1 |
| Shuldiner, A | 1 |
| Chai, S | 1 |
| Gesheff, T | 1 |
| Antonino, M | 1 |
| Gesheff, M | 1 |
| Zhang, Y | 1 |
| Tantry, US | 1 |
| Guda, N | 1 |
| Vakil, N | 1 |
| Sawhney, MS | 1 |
| Nelson, DB | 1 |
| Anagnostopoulos, GK | 1 |
| Kostopoulos, P | 1 |
| Margantinis, G | 1 |
| Tsiakos, S | 1 |
| Arvanitidis, D | 1 |
| Labenz, J | 2 |
| Petersen, KU | 1 |
| Rösch, W | 1 |
| Koelz, HR | 1 |
| Pohland, CJ | 1 |
| Scavnicky, SA | 1 |
| Lasky, SS | 1 |
| Good, CB | 1 |
| Laheij, RJ | 2 |
| Van Rossum, LG | 2 |
| Jansen, JB | 2 |
| Verheugt, FW | 2 |
| Lanas, A | 1 |
| Rodrigo, L | 1 |
| Márquez, JL | 1 |
| Bajador, E | 1 |
| Pérez-Roldan, F | 1 |
| Cabrol, J | 1 |
| Quintero, E | 1 |
| Montoro, M | 1 |
| Gomollón, F | 1 |
| Santolaria, S | 1 |
| Lorente, S | 1 |
| Cucala, M | 1 |
| Nuevo, J | 1 |
| Czuprynski, CJ | 1 |
| Faith, NG | 1 |
| Steinberg, H | 1 |
| Neudeck, B | 1 |
| Dohil, R | 1 |
| Newbury, RO | 1 |
| Sellers, ZM | 1 |
| Deutsch, R | 1 |
| Schneider, JA | 1 |
| Yun, HR | 1 |
| Bae, SC | 1 |
| Suzuki, H | 2 |
| Masaoka, T | 2 |
| Nomura, S | 1 |
| Hoshino, Y | 1 |
| Kurabayashi, K | 1 |
| Minegishi, Y | 1 |
| Suzuki, M | 1 |
| Ishii, H | 2 |
| Takahashi, S | 1 |
| Stupnicki, T | 1 |
| Dietrich, K | 1 |
| González-Carro, P | 1 |
| Straszak, A | 1 |
| Terjung, A | 2 |
| Thomas, KB | 2 |
| Lühmann, R | 2 |
| Fischer, R | 2 |
| Combe, B | 1 |
| Flipo, RM | 1 |
| Escalera Temprado, T | 1 |
| Banzo Marraco, J | 1 |
| Abós Olivares, MD | 1 |
| Olave Rubio, MT | 1 |
| Prats Rivera, E | 1 |
| García López, F | 1 |
| Razola Alba, P | 1 |
| Maev, IV | 2 |
| V'iuchnova, ES | 2 |
| Staseva, IV | 1 |
| Vlemmix, F | 1 |
| Khatibi E, A | 1 |
| Samsioe, G | 1 |
| Li, C | 1 |
| Lidfeldbt, J | 1 |
| Agardh, CD | 1 |
| Nerbrand, C | 1 |
| Hata, M | 1 |
| Shiono, M | 1 |
| Sekino, H | 1 |
| Furukawa, H | 1 |
| Sezai, A | 1 |
| Iida, M | 1 |
| Yoshitake, I | 1 |
| Hattori, T | 1 |
| Wakui, S | 1 |
| Soeda, M | 1 |
| Taoka, M | 1 |
| Negishi, N | 1 |
| Sezai, Y | 1 |
| Spiegel, BM | 1 |
| Chiou, CF | 1 |
| Ofman, JJ | 1 |
| Niv, Y | 1 |
| Robinson, M | 1 |
| Sener, G | 1 |
| Goren, FO | 1 |
| Ulusoy, NB | 1 |
| Ersoy, Y | 1 |
| Arbak, S | 1 |
| Dülger, GA | 1 |
| Canbakan, B | 1 |
| Mizrak, D | 1 |
| Keven, K | 1 |
| Kaygusuz, G | 1 |
| Kutlay, S | 1 |
| Sengul, S | 1 |
| Erbay, B | 1 |
| Sakai, G | 1 |
| Hibi, T | 1 |
| Horn, JR | 1 |
| Howden, CW | 2 |
| Declich, P | 1 |
| Tavani, E | 1 |
| Ferrara, A | 1 |
| Caruso, S | 1 |
| Bellone, S | 1 |
| Konno, M | 1 |
| Poncet, CM | 1 |
| Dupre, GP | 1 |
| Freiche, VG | 1 |
| Bouvy, BM | 1 |
| Demirkan, K | 1 |
| Bozkurt, B | 1 |
| Karakaya, G | 1 |
| Kalyoncu, AF | 1 |
| Ji, KY | 1 |
| Hu, FL | 1 |
| Regula, J | 1 |
| Butruk, E | 1 |
| Dekkers, CP | 1 |
| de Boer, SY | 1 |
| Raps, D | 1 |
| Simon, L | 1 |
| Campanozzi, A | 1 |
| Capano, G | 1 |
| Miele, E | 1 |
| Romano, A | 1 |
| Scuccimarra, G | 1 |
| Del Giudice, E | 1 |
| Strisciuglio, C | 1 |
| Militerni, R | 1 |
| Staiano, A | 1 |
| Cahan, MA | 1 |
| Balduf, L | 1 |
| Colton, K | 1 |
| Palacioz, B | 1 |
| McCartney, W | 1 |
| Farrell, TM | 1 |
| Brewster, UC | 1 |
| Perazella, MA | 1 |
| Cianciolo, G | 1 |
| Feliciangeli, G | 1 |
| Comai, G | 1 |
| Stefoni, S | 1 |
| Chen, YF | 1 |
| Jobanputra, P | 1 |
| Barton, P | 1 |
| Bryan, S | 1 |
| Fry-Smith, A | 1 |
| Harris, G | 1 |
| Taylor, RS | 1 |
| Saegusa, Y | 1 |
| Ichikawa, T | 1 |
| Iwai, T | 1 |
| Goso, Y | 1 |
| Ikezawa, T | 1 |
| Nakano, M | 1 |
| Shikama, N | 1 |
| Saigenji, K | 1 |
| Ishihara, K | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Wilde, MI | 2 |
| McTavish, D | 2 |
| Landes, BD | 1 |
| Petite, JP | 1 |
| Flouvat, B | 1 |
| Jacqz-Aigrain, E | 1 |
| Bellaich, M | 1 |
| Faure, C | 1 |
| Andre, J | 1 |
| Rohrlich, P | 1 |
| Baudouin, V | 1 |
| Navarro, J | 1 |
| Stolte, M | 1 |
| Creutzfeldt, W | 1 |
| Logan, RP | 1 |
| Gummett, PA | 1 |
| Misiewicz, JJ | 1 |
| Karim, QN | 1 |
| Walker, MM | 1 |
| Baron, JH | 1 |
| Papich, MG | 1 |
| Jonkers, D | 1 |
| Houben, P | 1 |
| Stobberingh, E | 1 |
| Stockbrügger, R | 1 |
| Langtry, HD | 1 |
| Schwartz, H | 1 |
| Krause, R | 1 |
| Siepman, N | 1 |
| Haber, M | 1 |
| Weissfeld, A | 1 |
| Kidd, S | 1 |
| Rose, P | 1 |
| Sahba, B | 1 |
| O'Connor, HJ | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Cunnane, K | 1 |
| Bashford, JN | 1 |
| Norwood, J | 1 |
| Chapman, SR | 1 |
| Lalkin, A | 1 |
| Loebstein, R | 1 |
| Addis, A | 1 |
| Ramezani-Namin, F | 1 |
| Mastroiacovo, P | 1 |
| Mazzone, T | 1 |
| Vial, T | 1 |
| Bonati, M | 1 |
| Koren, G | 1 |
| Henry, A | 1 |
| Batey, RG | 1 |
| Unge, P | 1 |
| Dajani, AI | 1 |
| Awad, S | 1 |
| Ukabam, S | 1 |
| Nounou, MA | 1 |
| Abdul Rasheed, Z | 1 |
| Gautam, S | 1 |
| Abdul Aal, G | 1 |
| Nayal, S | 1 |
| Pertusi, RM | 1 |
| Godwin, KS | 1 |
| House, JK | 1 |
| Knebl, JA | 1 |
| Alexander, JH | 1 |
| Rubin, BR | 1 |
| Forman, MD | 1 |
| Savarino, V | 1 |
| Neri, M | 1 |
| Vigneri, S | 1 |
| Evans, JS | 1 |
| Huffman, S | 1 |
| Humphries, TJ | 1 |
| Barth, J | 1 |
| Harewood, G | 1 |
| Daudén, E | 1 |
| Jiménez-Alonso, I | 1 |
| García-Díez, A | 1 |
| Horn, J | 1 |
| Soto Alvarez, J | 1 |
| Pilotto, A | 1 |
| Franceschi, M | 1 |
| Rassu, M | 1 |
| Leandro, G | 1 |
| Bozzola, L | 1 |
| Furlan, F | 1 |
| Di Mario, F | 1 |
| De Francesco, V | 1 |
| Stoppino, V | 1 |
| Sgarro, C | 1 |
| Faleo, D | 1 |
| Garnett, WR | 1 |
| Prescott, J | 1 |
| Pisegna, JR | 1 |
| Lebedev, EG | 1 |
| Dicheva, DT | 1 |
| Ovsiannikova, EV | 1 |
| Antonenko, OM | 1 |
| Shchekina, MI | 1 |
| Bujanda, L | 1 |
| Sánchez, A | 1 |
| Iriondo, C | 1 |
| Santos, A | 1 |
| Cosme, A | 1 |
| Muñoz, C | 1 |
| McCarthy, DM | 1 |
| Matheson, AJ | 1 |
| Jarvis, B | 1 |
| Scott, LJ | 1 |
| Dunn, CJ | 1 |
| Mallarkey, G | 1 |
| Sharpe, M | 1 |
| Logan, AJ | 1 |
| Morris-Stiff, GJ | 1 |
| Bowrey, DJ | 1 |
| Jurewicz, WA | 1 |
| Camara, DS | 1 |
| Corasanti, JG | 1 |
| Buckley, MM | 1 |
| Heel, RC | 1 |
| Farr, C | 1 |
| Georgieff, GS | 1 |
| Dotevall, G | 1 |
| Holt, S | 1 |
| Lamers, CB | 1 |
| Dols, DM | 1 |
| Gazzard, BG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers[NCT01557335] | Phase 1 | 30 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
33 reviews available for omeprazole and Cholera Infantum
| Article | Year |
|---|---|
Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Gastrointestinal Diseases; Gastrointestin | 2017 |
The pharmacology of esomeprazole and its role in gastric acid related diseases.
Topics: Clinical Trials as Topic; Drug Interactions; Esomeprazole; Gastrointestinal Diseases; Humans; Omepra | 2009 |
Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.
Topics: Child; Critical Illness; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Infusions, | 2010 |
Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Gastrointestinal Diseases; Huma | 2012 |
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clari | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
[What treatments can reduce the digestive complications of NSAIDs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Gastrointestinal Diseases; Histamine H2 Ant | 2003 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin | 2005 |
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastroesop | 2005 |
Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Enzyme Inhibitors; Gastrointes | 2005 |
[Helicobacter pylori eradication therapy for children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents | 2005 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; | 2006 |
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2006 |
[Protonic pump inhibitors in kidney transplant patients: efficacy and safety].
Topics: Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Eso | 2007 |
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Topics: Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Gastro | 2008 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
Topics: Gastric Acid; Gastrointestinal Diseases; Humans; Omeprazole | 1994 |
Clinical pharmacokinetics of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aging; Anti-Ulcer Agents; Drug Interactions; Gastrointestin | 1995 |
Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.
Topics: Achlorhydria; Animals; Gastrointestinal Diseases; Humans; Omeprazole; Risk Factors | 1994 |
Antiulcer therapy.
Topics: Animals; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cats; Cimetidine; Dog | 1993 |
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastrointestinal Diseases; | 1997 |
Antibiotic treatment of Helicobacter pylori infection.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Di | 1999 |
Update on medications used to treat gastrointestinal disease in children.
Topics: Anti-Bacterial Agents; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Child; Cisapride; Dru | 1999 |
Review article: rabeprazole's profile in patients with gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr | 1999 |
Helicobacter pylori and idiopathic chronic urticaria.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbo | 2000 |
The proton-pump inhibitors: similarities and differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr | 2000 |
The proton-pump inhibitors: similarities and differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr | 2000 |
The proton-pump inhibitors: similarities and differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr | 2000 |
The proton-pump inhibitors: similarities and differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr | 2000 |
Switching between intravenous and oral pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Cl | 2001 |
[Experience in the use of losek (omeprazole) in gastroenterology].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Double | 2001 |
Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastrointestinal Diseases; Hist | 2001 |
Lansoprazole: an update of its place in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2001 |
Update: gastroenterology and hepatology.
Topics: Chronic Disease; Esophageal Diseases; Gastrointestinal Diseases; Humans; Interferons; Liver Diseases | 1991 |
Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
Topics: Animals; Duodenal Ulcer; Esophagitis, Peptic; Gastrointestinal Diseases; Histamine H2 Antagonists; H | 1991 |
Omeprazole. Overview and opinion.
Topics: Duodenal Ulcer; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Omeprazole; Stomach Ulce | 1991 |
17 trials available for omeprazole and Cholera Infantum
| Article | Year |
|---|---|
Phytomedicine-based and Quadruple Therapies in Helicobacter pylori Infection: A Comparative, Randomized Trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Com | 2015 |
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Topics: Administration, Oral; Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Dose-Res | 2013 |
Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Azithromycin; Dose-Response Relationship, Drug; Drug Administration Schedu | 2003 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2003 |
[Comparative efficacy of different therapeutic schemes in gastropathies induced by nonsteroid anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Administration Schedule; | 2004 |
Health-related quality of life in patients with cardiovascular disease--the effect of upper gastrointestinal symptom treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiovascular Diseases; | 2004 |
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedu | 2005 |
Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2006 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration | 1996 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
The safety of omeprazole during pregnancy: a multicenter prospective controlled study.
Topics: Abnormalities, Drug-Induced; Adult; Birth Weight; Delivery, Obstetric; Enzyme Inhibitors; Female; Ga | 1998 |
Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, | 1999 |
One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimid | 1999 |
Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, | 2000 |
[Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Th | 2001 |
Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Child; Child, Preschool; Cyclosporine; Enzyme Inhibitors | 2002 |
48 other studies available for omeprazole and Cholera Infantum
| Article | Year |
|---|---|
Prospective observational study of the use of omeprazole and maropitant citrate in veterinary specialist care.
Topics: Animals; Dog Diseases; Dogs; Drug Prescriptions; Gastrointestinal Diseases; Hospitalization; Omepraz | 2020 |
Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Anesthesia, General; Anti-Bacterial Agents; Ant | 2017 |
First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target.
Topics: Albendazole; Amino Acid Sequence; Encephalitozoon; Fungal Proteins; Gastrointestinal Diseases; Gene | 2018 |
Changing prescription pattern of omeprazole among patients receiving clopidogrel.
Topics: Clopidogrel; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Follow-Up Studies; Ga | 2014 |
The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Topics: Adult; Aged; Aspirin; Budgets; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Female; Gast | 2017 |
[Topical issues of paediatric gastroenterology].
Topics: Child; Clarithromycin; Drug Therapy, Combination; Gastroenterology; Gastrointestinal Diseases; Helic | 2008 |
Confounding factors for variation of clozapine plasma levels: drug interactions with proton pump inhibitor or infectious etiologies?
Topics: Antipsychotic Agents; Clozapine; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Middl | 2011 |
Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area.
Topics: Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resis | 2010 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi | 2012 |
Low-dose aspirin: protection from the panacea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru | 2003 |
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; | 2003 |
Lansoprazole overutilization: methods for step-down therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Costs; Drug Utilization Review; Enz | 2003 |
Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; | 2003 |
Sodium pentobarbital anesthesia transiently enhances the severity of infection following intragastric, but not intravenous, inoculation of Listeria monocytogenes in mice.
Topics: Anesthesia; Animals; Anti-Ulcer Agents; Antidiarrheals; Cell Culture Techniques; Cell Line; Cimetidi | 2003 |
The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine.
Topics: Anti-Ulcer Agents; Child; Child, Preschool; Cysteamine; Cystinosis; Female; Gastric Acid; Gastrins; | 2003 |
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal | 2005 |
[Gastric uptake of gallium67 in the human immunodeficiency virus infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Aluminum Hydroxide; Anti-Bacterial Agents; Anti-Ulcer | 2004 |
Does hormone therapy increase allergic reactions and upper gastrointestinal problems? Results from a population-based study of Swedish woman. The women's health in the Lund area (WHILA) study.
Topics: Aged; Anti-Allergic Agents; Anti-Ulcer Agents; Climacteric; Cohort Studies; Female; Gastrointestinal | 2004 |
Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Protective effect of melatonin and omeprazole against alendronat-induced gastric damage.
Topics: Administration, Oral; Alendronate; Animals; Anti-Ulcer Agents; Antioxidants; Fasting; Female; Gastri | 2005 |
Gastric ulcer despite no acid in a renal allograft recipient: what is the link?
Topics: Adult; Anti-Ulcer Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Gastric Acid; Gastroi | 2005 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2005 |
Sporadic fundic gland polyps: clinico-pathologic features and associated diseases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Gastric Fundus; Gast | 2005 |
Long-term results of upper respiratory syndrome surgery and gastrointestinal tract medical treatment in 51 brachycephalic dogs.
Topics: Airway Obstruction; Analysis of Variance; Animals; Anti-Ulcer Agents; Cisapride; Dog Diseases; Dogs; | 2006 |
Impact of malnutrition on gastrointestinal disorders and gross motor abilities in children with cerebral palsy.
Topics: Adolescent; Body Mass Index; Cerebral Palsy; Child; Child Nutrition Disorders; Child, Preschool; Enz | 2007 |
Proton pump inhibitors reduce gallbladder function.
Topics: Adult; Enzyme Inhibitors; Female; Gallbladder; Gastrointestinal Diseases; Humans; Male; Movement; Om | 2006 |
Acute kidney injury following proton pump inhibitor therapy.
Topics: Anti-Ulcer Agents; Biopsy; Gastrointestinal Diseases; Humans; Kidney Glomerulus; Male; Middle Aged; | 2007 |
Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Animals; Anti-Ulcer Agents; Antimetabolites, An | 2008 |
Pharmacokinetics of intravenous omeprazole in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Critical Illness; Esophagitis; Gastric Acidity Determina | 1994 |
[Vision and hearing disorders with omeprazole: the facts].
Topics: Blindness; Deafness; Gastrointestinal Diseases; Germany; Humans; Omeprazole; Product Surveillance, P | 1995 |
Two-week eradication regimen for metronidazole-resistant Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Ciprofloxacin; Drug Resistanc | 1993 |
Ongoing gastric acid inhibition is a confounding factor in Helicobacter pylori diagnosis.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive System; Female; Gastric Acid; Gastric J | 1997 |
Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Prescriptions; Family Practice; Gas | 1998 |
Gastropathy induced by nonsteroidal anti-inflammatory drugs: prescribing patterns among geriatric practitioners.
Topics: Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Costs and Cost Analysis; | 1999 |
PPI-based triple therapy in the eradication of H. pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointest | 1999 |
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biological Availability; | 1999 |
[Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal | 2000 |
Lactobacillus acidophilus administration added to omeprazole/amoxycillin-based double therapy in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Defensins; Drug Therapy, Combination; Gastrointestinal Agents; G | 2000 |
Coprescribing proton pump inhibitors with other medications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Drug Interactions; Drug Prescriptions; Enzyme Inhibi | 2000 |
Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Topics: Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Gastrointestin | 2002 |
[New special drugs registered in Austria. Losec (omeprazole)].
Topics: Biological Availability; Gastrointestinal Diseases; Humans; Intestinal Absorption; Kidney; Liver; Om | 1991 |
[Drugs should never replace the art of medicine].
Topics: Adult; Female; Gastrointestinal Diseases; Histamine H2 Antagonists; Humans; Male; Omeprazole; Psycho | 1990 |
Omeprazole and acid inhibition: the essential issues. Proceedings of a symposium. London, April 1990.
Topics: Animals; Gastric Acid; Gastrointestinal Diseases; Humans; Omeprazole | 1990 |
Proceedings of the International Symposium on Omeprazole. Monte-Carlo, Monaco, 11-12 November 1988.
Topics: Animals; Gastrointestinal Diseases; Humans; Omeprazole | 1989 |
Clinical impact of H+, K+-ATP-ase inhibitors. Proceedings of a symposium. Maastricht, November 25, 1988.
Topics: Gastrointestinal Diseases; Humans; Omeprazole | 1989 |
The Dutch contribution to research and clinical experience with omeprazole.
Topics: Gastrointestinal Diseases; Humans; Netherlands; Omeprazole; Research | 1989 |
Omeprazole.
Topics: Animals; Dogs; Gastric Acid; Gastric Mucosa; Gastrointestinal Diseases; Humans; Omeprazole; Rats | 1989 |